Biotech Values

[DewDiligence]

COCP PR on 6w HCV regimen:

https://www.globenewswire.com/news-release/2019/10/30/1937841/0/en/Cocrystal-Pharma-Announces-New-Data-on-CC-31244-and-Abstract-Acceptance-for-Poster-Presentation-at-the-AASLD-2019-Liver-Meeting.html

Eight of 12 patients achieved primary endpoint of sustained virologic response (SVR), which is considered a cure, using only 6 weeks of Epclusa’s therapy combined with only 2 weeks of CC-31244

As though a 67% SVR rate were something to boast about.

See #msg-146258764 for related info.